Brief: Compugen Doses First Patient In Phase 1/2 Triple Combination Cohort Expansion Of COM701
19/07/2021 13:50
July 19 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN DOSES FIRST PATIENT IN PHASE 1/2 TRIPLE
COMBINATION
COHORT EXPANSION OF COM701 WITH OPDIVO® AND BRISTOL MYERS
SQUIBB'S ANTI-TIGIT ANTIBODY, BMS-986207
* COMPUGEN LTD - PRELIMINARY DATA FROM TRIPLE COMBINATION
DOSE
ESCALATION ON-TRACK FOR Q4 2021
Source text for Eikon: ID:nPn6YhgLna
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025